Drug Type Gene therapy |
Synonyms Compacted DNA, DNA nanoparticle gene therapy, Plasmid DNA vector expressing cystic fibrosis transmembrane gene + [1] |
Target |
Action stimulants |
Mechanism CFTR stimulants(Cystic fibrosis transmembrane conductance regulator stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cystic Fibrosis | Phase 2 | United States | 20 Jan 2003 |
Not Applicable | - | - | (Transtracheal application of sec-R targeted compacted pCMV FIX plasmid) | imaqeboxxk(qzejmtszrf) = clzfqofsat pxwrkonqga (ayahralzsq ) | - | 01 May 2004 | |
(Sec-R targeted pCMV FIX injected intravenously via the tail vein) | imaqeboxxk(qzejmtszrf) = ebxlpyyaia pxwrkonqga (ayahralzsq ) | ||||||
Phase 1/2 | Cystic Fibrosis basal nasal potential difference (NPD) | FEV1 | 12 | CFTR001 Gene Transfer Vector (Compacted DNA in Saline) | ocjqbriots(cfslrcfnlc) = all other adverse events were grade I in severity, and none were felt to be due to compacted DNA exposure sfmpcsaxxj (ncgjrqwdls ) View more | Positive | 01 May 2003 |